818TiP A pivotal phase II, randomized, controlled, open-label, trial (MIZAR-003) to assess the efficacy and safety of GC101 TIL, an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, for patients with advanced anti-PD-1 refractory melanoma in later-line therapy